Skip to main content
. 2021 Oct 5;6:119. doi: 10.1038/s41541-021-00382-9

Fig. 3. Triple immunization of VP1/CRA induced strong and durable antitumor effect.

Fig. 3

a An outline of the treatment schedule. CMS5-VP1 tumor cells at 1 × 106 per mouse were subcutaneously inoculated into the left flank back of BALB/c mice on day 0. b When tumors were palpable on day 5, tumor-bearing mice were randomly divided and immunized with VP1/CRA, VP1/A, CRA, and PBS thrice at 1-week intervals. c To evaluated the durable antitumor effects induced by triple treatment of VP1/CRA, tumor-free mice were rechallenged with CMS5-VP1 tumor cells at 1 × 106 per mouse in the right flank back on day 49. Tumors were measured with digital calipers and tumor volumes were calculated.